NovaBridge Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-176.68	-99.39	-164.43	-282.41	-366.83
Depreciation & Amortization	0.07	0.26	0.48	0.21	2.29
Stock-Based Compensation	5.97	-1.95	10.24	13.15	95.75
Other Adjustments	44.63	1.53	35.93	61.17	53.61
Change in Receivables	-	-	-	1.55	11.18
Changes in Inventories	-	-	-	-	-4.29
Changes in Accrued Expenses	18.08	-0.21	-35.68	18.34	23.93
Changes in Unearned Revenue	-	-	-	-	35.24
Changes in Other Operating Activities	-1.01	-30.1	-111.23	-119.45	-3.99
Operating Cash Flow	-20.6	-52.67	-72.7	-49.58	-153.1
Capital Expenditures	-0.01	-0.05	-0.16	-2.09	-4.71
Sale of Property, Plant & Equipment	0.05	0.06	-	-	-
Purchases of Investments	-49.96	-245.86	-100	-767.51	-1,601
Proceeds from Sale of Investments	154.89	109.83	85	764.42	1,492
Other Investing Activities	-	-22.29	26.08	73.22	-0.94
Investing Cash Flow	104.97	-136.02	-15.16	-5.18	-114.41
Issuance of Common Stock	61.91	-	0.41	6.92	94.99
Repurchase of Common Stock	-	-0.34	-8.64	-3.01	-
Net Common Stock Issued (Repurchased)	61.91	-0.34	-8.24	3.91	94.99
Other Financing Activities	-4.19	-4.17	9.91	2.81	-1.55
Financing Cash Flow	57.73	-0.34	-8.24	3.91	93.44
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.28	0.57	5.2	14.2	-20.26
Net Cash Flow	142.37	-242.4	-164.7	-77.3	-194.33
Free Cash Flow	-20.6	-52.72	-72.86	-51.67	-157.81
FCF Margin	-	-	-11528.60%	3331.59%	-1139.46%
Free Cash Flow Per Share	-0.22	-0.65	-0.88	-0.63	-2.08
Levered Free Cash Flow	-29.13	-52.33	-354.33	-474.06	-318.35
Unlevered Free Cash Flow	-77.13	-81.52	-218.62	-156.04	-277.85

SEC Filings: 10-K · 10-Q